Article

Biolight gains glaucoma treatment patent

BioLight Israeli Life Sciences Investments’ ViSci, its wholly owned subsidiary, has been informed that the FDA has granted a patent number covering the proprietary formulation of its glaucoma treatment, latanoprost, by the U.S. Patent and Trademark Office.

 

Tel-Aviv, Israel-BioLight Israeli Life Sciences Investments’ ViSci, its wholly owned subsidiary, has been informed that the FDA has granted a patent number covering the proprietary formulation of its glaucoma treatment, latanoprost, by the U.S. Patent and Trademark Office.

The patent is intended to protect, inter alia, the chemical structure of the active ingredient for the treatment. The patent is also covering the release of the active ingredient from the Eye-D subconjunctival insert and its use in treating elevated IOP in patients with glaucoma and ocular hypertension.

The patent and its registration will be in effect at least until April 2030.

ViSci holds an exclusive option from Novaer to a worldwide exclusive license for any use of the insert's proprietary technology.

 

Recently, ViSci has completed an ocular toxicology and safety study in animals and has filed an Investigational New Drug application with the FDA to conduct a phase I/IIa clinical study with the treatment.

The study will be conducted at up to 7 investigative sites in the United States.

"We believe that our (insert) will provide an effective solution to the well-known poor compliance with chronic eye-drop administration commonly used today as a treatment for glaucoma,” said Suzana Nahum-Zilberberg, BioLight's chief executive officer. “This U.S. patent approval will strengthen our business, marketing, and competitive advantages of our company."

 

 

For more articles in this issue of Ophthalmology Times eReport, click here.

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.